Structural Vulnerabilities in DLBCL for Enhanced Treatment Strategies

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is often immune-suppressed, limiting responses to immunotherapies.
• A specific tumor stroma, characterized by activated myofibroblast-like cells, has been linked to better patient outcomes in DLBCL.

Purpose of the Study:

• To investigate the role of fibroblastic reticular cells (FRCs) in the DLBCL tumor microenvironment.
• To understand how DLBCL cells interact with and alter FRCs.
• To identify potential therapeutic strategies targeting the FRC network.

Main Methods:

• Phenotypic, transcriptional, and functional analysis of FRCs in human and murine DLBCL models.
• High-dimensional imaging mass cytometry to analyze immune cell neighborhoods.
• Ex vivo modeling of the tumor microenvironment.

Main Results:

• DLBCL cells activate and remodel FRCs, promoting a chronic inflammatory state that supports cancer cell survival.
• Reprogrammed FRCs inhibit CD8+ T-cell migration and function by altering chemokines, adhesion molecules, and antigen presentation.
• Heterogeneous FRC and T-cell interactions correlate with clinical outcomes.
• Targeting the FRC network can enhance T-cell infiltration and effector functions.

Conclusions:

• DLBCL pathogenesis involves FRC activation, creating an immunosuppressive microenvironment that hinders anti-tumor immunity.
• FRCs represent a druggable target within the DLBCL tumor microenvironment.
• Modulating FRCs offers a promising strategy for combination therapies to improve treatment efficacy in DLBCL.